GlassScriptPhysician profile
Maria K Jones
NPI 1174987473
$14,561.08
in general payments reported to CMS, 2019-2025
36 companies · $3,621 in 2025
The $3,621 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,847 · 2022: $2,179 · 2023: $3,213 · 2024: $3,701 · 2025: $3,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,540 · Consulting Fee: $736 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,539.75 |
| Consulting Fee | $736.00 |
| Education | $258.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,982.71 | 2021-2025 | Evenity, Krystexxa, Prolia |
| Abbvie INC. | $2,863.52 | 2021-2025 | |
| Janssen Biotech, INC. | $1,390.44 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,216.03 | 2021-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $959.92 | 2022-2025 | Orencia |
| Lilly USA, LLC | $706.95 | 2021-2025 | Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $400.36 | 2022-2025 | Saphnelo, Flumist Quadrivalent |
| Novartis Pharmaceuticals Corporation | $392.81 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $381.48 | 2021-2025 | Acthar |
| Glaxosmithkline, LLC. | $299.04 | 2021-2025 | Benlysta, Nucala |
| Pfizer INC. | $269.88 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $255.65 | 2022-2023 | Tremfya |
| Radius Health, INC. | $242.11 | 2021-2025 | Tymlos |
| Horizon Therapeutics Plc | $239.01 | 2021-2023 | |
| Sobi, INC | $212.78 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $206.66 | 2022-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $205.13 | 2023-2025 | Strensiq, Ultomiris |
| Aurinia Pharma U.S., INC. | $189.84 | 2022-2025 | Lupkynis |
| Octapharma USA, INC. | $185.32 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Fresenius Kabi USA, LLC | $131.10 | 2023-2025 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.73 | 2021-2025 | Ofev, Cyltezo |
| Actelion Pharmaceuticals US, INC. | $122.43 | 2021-2022 | |
| Solventum Corporation | $112.18 | 2024 | V.A.C. Dermatac, Activ.A.C., Promogran Prisma |
| Molnlycke Health Care US, LLC | $85.82 | 2024 | Mepilex Border Flex, Mepilex Border Sacrum |
| Genzyme Corporation | $53.78 | 2023-2025 | |
| Organon LLC | $50.35 | 2021-2024 | |
| Invivyd INC | $48.94 | 2025 | Pemgarda |
| Arcutis Biotherapeutics, INC. | $48.60 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $41.18 | 2024 | Arcalyst |
| Pacira Therapeutics, INC. | $31.57 | 2021 | |
| Genentech USA, INC. | $25.27 | 2025 | Gazyva |
| Oxford Immunotec USA INC | $19.70 | 2022 | |
| Mylan Institutional INC. | $18.15 | 2023 | Hulio |
| Sandoz INC. | $15.02 | 2023 | Hyrimoz |
| Merck Sharp & Dohme LLC | $14.69 | 2021 | |
| Scilex Pharmaceuticals INC. | $13.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.